Veterans hooked on fishing; raising funds for upcoming trip
DES MOINES, Iowa — This local group of veterans is pretty fly, and they're currently raising funds for a three-day fly-fishing trip.
Project Healing Waters started 20 years ago as a project to help disabled veterans keep active and busy. The group has since expanded to allow all veterans, and now thousands partake across the country.
The Des Moines group gathers once a week to learned tricks of the trade, build flies, and spend time with friends. The group then goes on fly-fishing trips around the metro and put those flies to good use.
One veteran in the program says the group has helped him overcome obstacles and improve his mental and physical health.
Greenfield Mercantile breathes new life into historic storefront
'I live with MS and the first day I was able to come in and participate. I have issues with my hands with dexterity and sometimes tremors, and they showed me how to use the virus and tied my first fly. After about 45 minutes to an hour, my hands had actually settled down, no longer shaking,' said Jeff Cook, Project Healing Waters member for six years.
Project Healing Waters isn't only about keeping veterans active, it also gives them a space to feel at peace and share their experiences.
'This is part of what happens when you go out. You are focused on fishing. You forget everything around you except you have the unusual come in. And this is so fantastic,' said Paul Wright, PHW Lead. 'I've been through the ringer, so I understand. When we get together, we don't ask questions. You talk. Fine. You don't want to talk, don't matter. We don't care. We're here to provide support.'
The group is currently raising funds to attend a special three-day trip to Strawberry Point from May 16-18, where Iowa stream trout fishing is at its finest.
'This area is very beneficial to us. For one, it we don't have public people in the area. We don't have a busy restaurant.,' said Ronda Long, Trout Unlimited President. 'My veterans with PTSD, they really need a calm, quiet area. The trout streams are right there.'
To learn more about Project Healing Waters mission you can visit their website or contact the Des Moines program lead Paul Wright at 515-229-3299. To donate to the trip, you can contact Paul Wright or Ronda Long at 319-280-2973.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Elle
5 hours ago
- Elle
Science Unpacks the Healing Potential of Your Own Blood
Every item on this page was chosen by an ELLE editor. We may earn commission on some of the items you choose to buy. If you were to shrink yourself down to smaller than a sugar crystal and travel into someone's veins like Ms. Frizzle and her Magic School Bus, you'd see that blood isn't the free-flowing river depicted in your childhood storybooks. Rather, you'd find an intricate ecosystem suspended in plasma: disc-like red blood cells carrying oxygen through the body; bumpy white blood cells warding off infection; and tiny platelets with octopus-like tentacles directing healing. Rich in growth factors, platelets are often considered the gold standard for regenerative medicine. In platelet-rich plasma treatments, or PRP, doctors spin a patient's blood in a centrifuge to single out the platelets and the plasma, creating a healing elixir that can be added back into a patient's body. PRP has long been used for promoting hair growth, improving skin, and healing injuries. The next generation of PRP is called PRF, which may offer more sustained healing and collagen production over time. 'PRF stands for 'platelet-rich fibrin,'' says Lara Devgan, MD, a plastic surgeon in New York. 'It harnesses the body's own growth factors to stimulate collagen, improve skin texture, and restore volume without fillers.' For patients, PRP and PRF extractions for cosmetic or therapeutic use just involve a simple blood draw. They're much less expensive than a hair transplant, and may produce a more natural result than other skin injectables. If PRP is an iPhone, PRF is the Pro version, leading to potentially longer-lasting results. This may be because it contains fibrin, which aids in blood clotting; a 2011 study in Annals of Maxillofacial Surgery found that PRF may speed healing, since it helps the body form new blood vessels. Thanks to fibrin, PRF unleashes growth factors more slowly than PRP. Because it's mixed at a higher speed, PRP expels a flood of growth factors—which act like messengers between and within cells, pinging information back and forth to ensure everything is in tip-top shape—all at once. In contrast, PRF releases these healing agents over 7 to 10 days, which may enhance tissue regeneration, says Gabriel Chiu, DO, a plastic surgeon in Beverly Hills. PRF was developed to bypass some of PRP's limits. PRP is often mixed with anticoagulants, which in some cases may cause allergic reactions and hinder the platelets' regenerative power, according to a 2020 study published in Frontiers in Bioengineering and Biotechnology. PRF, which is spun more slowly, is made without anticoagulants and so 'has the least risk for someone [with] sensitivity issues,' Chiu explains. Still, both Devgan and Chiu agree that in some cases, PRP remains the better option. It's an easier-to-disperse fluid, so it's better for larger treatment areas. PRP is best for hair loss, since it can be micro-needled in, whereas PRF's thicker solution must be injected. But when it comes to targeted treatment for lines, wrinkles, and hollow under-eyes, PRF may be the more potent remedy since it softens the face, according to Chiu. He also uses PRF as a 'glue' when he does a facelift. It helps tissues adhere to each other, and may boost healing. Though PRF can appear to 'fill' under-eye hollows by helping skin quality and firmness, it won't add volume, like filler. A PRF treatment is akin to upping the thread count of your sheets, Devgan says. Skin enhanced by PRF versus normal skin is like the difference between sheets made from 350-thread-count Egyptian cotton and run-of-the mill 200-thread-count sheets. 'It's not like making a bedsheet into a comforter,' she says. But who doesn't want an amazing set of sheets? A version of this story appears in the Summer 2025 issue of ELLE. GET THE LATEST ISSUE OF ELLE
Yahoo
21 hours ago
- Yahoo
Wildfire smoke can harm your brain, not just your lungs
Wildfires are already burning in parts of Canada, and as they do, many communities are already facing the familiar thick haze as smoke drifts in. Smoke from wildfires has already led Environment Canada to issue air quality warnings for much of Ontario. In Toronto, smoke led to the city briefly having the worst air quality in the world. Anyone who has experienced wildfire smoke knows how it can leave you with a scratchy throat, stinging eyes and impact your lungs. However, smoke can also affect your brain. Tiny airborne pollutants found in smoke have been linked to increased risk of stroke, dementia and flare-ups in neurological diseases like multiple sclerosis (MS). These effects can disproportionately impact older adults, people with disabilities, Indigenous Peoples and those living in low-income communities. This isn't just about climate. It's about equity, and health systems need to catch up. Canada's 2023 wildfire season was the worst on record, and as climate change worsens wildfires, it may be a sign of what's to come. Alongside harmful gases and heavy metals, wildfire smoke contains fine particulate matter, also known as PM2.5. These tiny particles can travel deep into your lungs, slip into your bloodstream and even reach your brain. Some even bypass the lungs entirely, entering the brain directly through the nose. After entering the brain, these toxins can cause inflammation and stress, damage nerve cells and even accelerate cognitive decline. Studies have linked exposure to air pollution to an increased risk of stroke and dementia. Even short-term spikes in smoke exposure, like those during wildfires, lead to a surge in emergency visits for strokes, especially among people over 65. A 2022 experiment had thousands of adults participate in an online attention task under smoky conditions. It found that just a three-hour spike in fine particulate matter, typical of a heavy smoke episode, led to measurably worse attention scores. This fits other evidence that breathing smoke makes people mentally foggy, forgetful or fatigued. In 2024, a study found that chronic exposure to wildfire-related air pollution significantly increased the likelihood of someone being diagnosed with dementia. The risk was most pronounced in low-income communities, where people often have less access to clean air, health care and protective measures. For people already living with neurological conditions like MS or Parkinson's disease, the stakes are even higher. Exposure to fine particulate pollution has been linked with increased hospital admissions for MS relapses, particularly in young patients. Other research points to worsening symptoms of epilepsy and cognitive decline under extreme heat and polluted air conditions. Despite these mounting risks, neurological health considerations have been largely absent from wildfire preparedness initiatives and public health responses. That needs to change. If you want to stay informed about local smoke exposure, tools like AQmap can help you track PM2.5 levels in real time across Canada. Some face far greater risk from wildfire smoke than others, including older adults, those with pre-existing health conditions, people with lower socio-economic status, Indigenous populations, people residing in remote areas and children. This is a health equity issue as much as a medical one. Each of these groups faces unique and compounding challenges during smoke events. For example, older adults are more vulnerable to the cardiovascular and neurological effects of smoke. They also face greater barriers to accessing filtered environments. People with disabilities or chronic illnesses, including those with neurological conditions, often can't relocate during smoke events and may rely on power-dependent medical devices that can fail during climate emergencies. Low-income families are more likely to live in housing without proper air filtration or cooling. These same communities often face higher baseline rates of neurological disease. Indigenous communities, more than 80 per cent of which are located near fire-prone areas, face recurring displacement, interruptions to care and disproportionate exposure to smoke each summer. Children and adolescents are particularly susceptible to the harmful neurological effects of wildfires. Because their brains are still developing and they breathe more air per body weight than adults, children are especially vulnerable to harmful pollutants. Studies have linked early-life exposure to fine particulate matter with an increased risk of neuro-developmental disorders, lower cognitive function and structural brain changes. These populations aren't just more exposed, they also have fewer resources to respond. Recognizing these inequities, we are developing a climate-health equity framework for Canada, with a specific focus on neurological health. Our interdisciplinary team is asking: how can we build health systems that protect vulnerable brains during climate emergencies? Health-care workers in Alberta Health Services have designed the Climate-Resilient Acute Care Clinical Operations Framework. This framework supports hospitals in becoming both greener and more resilient, ensuring care can continue during wildfires, floods and extreme heat events. Importantly, it also centres the needs of equity-deserving populations, integrating climate adaptation into emergency care, supply chains, staffing and patient communication. What needs to change? Public awareness must expand beyond respiratory health. Neurological effects of smoke should be included in public health messaging, especially for high-risk groups. Health systems must be climate-ready, with clean air shelters, evacuation protocols and services tailored to meet the needs of neurological patients. Communities need support, from funding for air filtration to co-ordinated outreach during smoke events. Indigenous-led fire stewardship and community health initiatives should be part of national planning. Supporting Indigenous-led fire stewardship not only strengthens wildfire response but also respects Indigenous sovereignty and traditional ecological knowledge. Clinicians must be empowered to address climate-related health risks. Training in environmental health, including its impact on the brain, is increasingly essential. Wildfire season is back, and with it, an urgent need to protect more than just our lungs. The science is clear: breathing smoky air affects our minds, especially for those already facing health and social vulnerabilities. Climate change is a brain health issue. Building a healthier, more equitable future requires us to treat it that way, starting now. This article is republished from The Conversation, a nonprofit, independent news organisation bringing you facts and trustworthy analysis to help you make sense of our complex world. It was written by: Dr Bhavini Gohel, University of Calgary and Muskaan Muse Laroyia, University of Calgary Read more: Managing forests and other ecosystems under rising threats requires thinking across wide-ranging scenarios As wildfires become more frequent and intense, how will persistent smoke exposure affect long-term health? Wildfire season is changing in Canada — posing even greater risks to the nation's communities and ecosystems Dr Bhavini Gohel works for the Canadian Coalition for Green Healthcare. Muskaan Muse Laroyia does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.
Yahoo
4 days ago
- Yahoo
Demyelinating Diseases Therapeutics Market to Reach USD 45 Billion by 2034, Growing at 6.3% CAGR
Demyelinating Diseases Therapeutics Market Outlook 2025-2034 Luton, Bedfordshire, United Kingdom, June 06, 2025 (GLOBE NEWSWIRE) -- The global market for demyelinating diseases therapeutics is witnessing notable growth and transformation, fueled by the increasing prevalence of neurological disorders and the introduction of innovative treatment solutions. Valued at approximately USD 25 billion in 2024, the market is projected to reach an estimated USD 45 billion by 2034, progressing at a steady Compound Annual Growth Rate (CAGR) of 6.3% during the forecast period from 2025 to 2034. Download PDF Brochure: A major contributor to this expansion is the rising incidence of multiple sclerosis (MS), along with other related disorders such as neuromyelitis optica (NMO), acute disseminated encephalomyelitis (ADEM), and chronic inflammatory demyelinating polyneuropathy (CIDP). The market is undergoing significant advancements through personalized medicine, biologics, and digital health integrations, shaping the way therapies are developed and delivered. Market Segmentation: A Detailed Breakdown The demyelinating diseases therapeutics market is categorized across several parameters including product type, therapeutic application, disease type, route of administration, distribution channels, therapeutic class, and patient demographics. Among product types, monoclonal antibodies, corticosteroids, and immunomodulators dominate due to their high efficacy and role in managing autoimmune responses central to these diseases. Multiple Sclerosis (MS) remains the largest disease segment due to its global prevalence, impacting nearly 2.8 million individuals worldwide. This segment benefits from a strong drug pipeline and sustained investment in research and development. In contrast, diseases like NMO and CIDP, though less prevalent, are becoming more prominent due to improved diagnostic capabilities and novel drug approvals. When it comes to therapeutic applications, Disease-Modifying Therapies (DMTs) are pivotal. These therapies reduce relapse rates and slow disease progression, particularly in MS, capturing the lion's share of the market. Symptomatic treatments, though secondary in market size, are essential for improving patients' quality of life and remain indispensable in overall disease management strategies. Route of Administration and Distribution Channels The preferred routes of administration in this market include injectable, oral, and infusion-based methods. Injectables lead due to their rapid efficacy and widespread use in administering monoclonal antibodies. However, oral therapies are quickly gaining popularity for their convenience and higher patient adherence, which could shift the administration landscape in coming years. From a distribution perspective, hospital pharmacies remain the dominant channel, especially for therapies requiring medical supervision or administration. Meanwhile, online pharmacies are emerging as strong contenders due to their convenience and role in chronic disease management. This growth is driven by increased internet penetration, telehealth services, and changing consumer behavior. Therapeutic Class and Demographic Insights In terms of therapeutic classification, biologics are leading the charge. These include monoclonal antibodies and recombinant proteins that target specific immune pathways. Biologics offer superior efficacy and fewer side effects, making them the preferred option in many treatment regimens. However, small molecules continue to hold value due to their affordability, oral availability, and ease of production, especially in cost-sensitive markets. Demographically, adult patients comprise the majority due to the typical onset age of MS and related disorders. However, pediatric treatments are on the rise as early diagnosis improves. The geriatric population is another growing segment, supported by the aging global population and increasing incidence of neurological conditions in older adults. These patients often require specialized care due to comorbidities and age-related drug interactions. Browse full Report - Market SegmentationType of Demyelinating Disease - Multiple Sclerosis (MS) - Neuromyelitis Optica (NMO) - Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Acute Disseminated Encephalomyelitis (ADEM) Therapeutic Application - Disease-Modifying Therapies (DMTs) - Symptomatic Treatments - Corticosteroids - Monoclonal Antibodies - Other Immunotherapies & Supportive Care Route of Administration - Oral - Injectable (Subcutaneous, Intravenous) - Infusion Distribution Channel - Hospital Pharmacy - Retail Pharmacy - Online Pharmacy Therapeutic Class - Biologics - Small Molecules - Non-Biologics Patient Demographics - Adults - Pediatric - Geriatric Regional Insights and Global Landscape North America currently commands the largest market share, accounting for around 45% of global revenue in 2024. This dominance is underpinned by advanced healthcare systems, widespread access to therapies, and high levels of R&D investment. The U.S., in particular, plays a significant role with supportive regulatory policies and well-established pharmaceutical players. Europe follows closely, contributing approximately 30% to the market. Growth in this region is propelled by increasing awareness, government-supported healthcare systems, and a favorable environment for clinical research. Countries like Germany, France, and the UK are key hubs for drug development and patient care. The Asia-Pacific region is the fastest-growing market with a projected CAGR of 8% through 2034. Factors such as economic development, expanding healthcare infrastructure, and rising disease prevalence contribute to this rapid growth. Nations like China, India, and Japan are investing heavily in healthcare, which supports both access and innovation in therapeutic offerings. Latin America and the Middle East & Africa are also emerging as regions with untapped market potential. While they currently hold smaller shares, their projected CAGRs of 7% and 6% respectively reflect strong future growth, particularly in urban centers with improving access to care. Key Market Drivers The momentum in this market is largely attributed to scientific and technological advancements, including the development of next-generation therapies like monoclonal antibodies and targeted biologics. The rise of personalized medicine, where treatments are tailored based on patient-specific genetic and biomarker profiles, is reshaping therapeutic strategies. Regulatory developments are also influential. Accelerated approval pathways, especially for orphan and breakthrough therapies, have reduced time-to-market for promising treatments. In tandem, increased global healthcare spending, particularly in neurological and autoimmune sectors, is bolstering the adoption of advanced therapies. Challenges and Restraints Despite promising growth, the market faces a number of hurdles. One major challenge is the high cost of therapies, especially biologics, which limits access for patients in low- and middle-income regions. Prolonged regulatory approval timelines and complex compliance requirements can also delay product launches and increase costs for manufacturers. Supply chain disruptions, particularly in biopharmaceutical manufacturing, further complicate delivery and availability. The sector is also vulnerable to clinical trial failures, which can derail product pipelines and investor confidence. Additionally, generic and biosimilar competition can undercut revenues once patents expire, necessitating continuous innovation. Buy Now : Opportunities and Emerging Trends The market is rich with opportunities for expansion and innovation. Digital health technologies, such as telemedicine platforms and remote monitoring tools, are increasingly integrated into care pathways, enhancing both outcomes and convenience. These technologies also support real-time data collection and predictive analytics, aiding personalized care. Additionally, emerging markets offer considerable potential for growth. As awareness rises and infrastructure improves, pharmaceutical companies are investing in these regions to tap into large, underserved patient populations. The trend toward strategic partnerships, mergers, and acquisitions is another significant development. Collaborations between pharmaceutical firms and tech companies, particularly in AI-driven drug discovery and patient management, are redefining the way therapies are developed and delivered. Key Competitors Biogen Inc. Novartis International AG Roche Holding AG Sanofi S.A. Celgene Corporation (a Bristol-Myers Squibb Company) Merck KGaA Teva Pharmaceutical Industries Ltd. Genzyme Corporation (a Sanofi Company) EMD Serono, Inc. AbbVie Inc. GSK (GlaxoSmithKline) Vertex Pharmaceuticals Incorporated Pfizer Inc. Janssen Pharmaceuticals (a Johnson & Johnson Company) Horizon Therapeutics plc Recent Strategic Developments Company Name: Biogen Inc. Month & Year: August 2023 Type of Development: Product Launch Detailed Analysis: Biogen launched its latest multiple sclerosis (MS) therapy, an oral medication named Alectinib, in August 2023. This drug represents a significant advancement in the treatment landscape for MS, targeting a previously underserved patient demographic. The launch is crucial as the MS market increasingly shifts toward oral therapies that offer improved safety and convenience over traditional injections. Biogen's investment in clinical studies demonstrates their commitment to addressing unmet clinical needs. The release not only strengthens Biogen's portfolio but also rekindles competitive dynamics in the MS therapeutics market. Other companies may need to accelerate their research and focus on innovative delivery mechanisms to retain market share, indicating a potential uptick in R&D spending across the industry. Company Name: Novartis International AG Month & Year: July 2023 Type of Development: Regulatory Approval Detailed Analysis: In July 2023, Novartis received expedited approval from the FDA for its drug ofatumumab aimed at treating neuromyelitis optica spectrum disorder (NMOSD). NMOSD is a rare, debilitating condition, and this regulatory advancement opens new pathways for patients who have historically faced limited treatment options. This approval underlines a broader trend in the industry towards personalized medicine and targeted therapies. The positive regulatory news also strengthens Novartis's position in the demyelinating diseases market, compelling competitors to prioritize novel therapeutic approaches. As regulatory environments evolve, this approval may set a precedent that encourages pharmaceutical companies to innovate and invest heavily in rare disease therapies. Company Name: AbbVie Inc. Month & Year: September 2023 Type of Development: Merger Detailed Analysis: AbbVie entered a strategic merger with a biotech firm specializing in CNS (central nervous system) diseases in September 2023. This merger is pivotal not only for AbbVie's growth but also signifies a consolidation trend within the CNS therapeutics sector. By integrating innovative technologies and pipeline assets, AbbVie aims to bolster its competitive edge significantly in the demyelinating diseases market. This merger highlights the increasing interconnectedness of the pharmaceutical ecosystem, pivoting around collaboration to enhance therapeutic effectiveness and patient outcomes. Industry observers anticipate that this will prompt increased mergers and acquisitions in the sector as firms seek similar synergies to expedite drug development processes. Company Name: Sanofi S.A. Month & Year: October 2023 Type of Development: Product Launch Detailed Analysis: Sanofi unveiled a new monoclonal antibody therapy for treating relapsing forms of MS in October 2023, expanding its treatment arsenal significantly in this field. The introduction of this therapy reflects a commitment to advancing treatment modalities through innovative science. Furthermore, the development showcases a broader industry trend toward biologics and targeted therapies for demyelinating diseases. Market responses indicate that healthcare professionals and payers are eager for alternatives that provide safety and efficacy. This influx of new treatment options may fuel competitive pressure on existing therapies, leading to potential price adjustments and altering market dynamics. Company Name: Teva Pharmaceutical Industries Ltd. Month & Year: November 2023 Type of Development: Partnership Detailed Analysis: Teva announced a strategic partnership with a technology firm to collaborate on AI-driven approaches to MS treatment and patient management in November 2023. This partnership underscores a growing trend of incorporating technology into healthcare to enhance drug discovery and patient outcomes. By utilizing AI, Teva aims to streamline clinical research and tailor therapies to individual patient needs, thereby enhancing therapeutic efficacy. The collaboration could reshape how the pharmaceutical industry conducts research and develops therapies for demyelinating diseases, prompting competitors to explore similar integrations of advanced technologies, ultimately driving innovation in the market. This report is also available in the following languages : Japanese (脱髄疾患治療薬市場), Korean (탈수초성 질환 치료제 시장), Chinese (脱髓鞘疾病治疗市场), French (Marché des thérapies contre les maladies démyélinisantes), German (Markt für Therapeutika gegen demyelinisierende Erkrankungen), and Italian (Mercato terapeutico delle malattie demielinizzanti), etc. Request Sample Pages: More Research Finding – Human Granulocytic Ehrlichiosis Drug Market The market for drugs targeting Human Granulocytic Ehrlichiosis (HGE) is valued at approximately $320 million. Given the rising incidence of tick-borne diseases and increased awareness among healthcare professionals, the market is projected to grow significantly, reaching an estimated value of $580 million by 2034. This indicates a compound annual growth rate (CAGR) of 6.1% during the forecast period from 2025 to 2034. Lymphopenia Therapeutics Market The global lymphopenia therapeutics market is valued at approximately $3.2 billion, driven by increasing awareness of immune disorders and advancements in biologics and immunotherapies. The market is projected to grow significantly, reaching an estimated $6.8 billion by 2034, reflecting a robust Compound Annual Growth Rate (CAGR) of around 8.1% during the forecast period of 2025 to 2034. Cytochrome C Antibody Market The global Cytochrome C Antibody market is valued at approximately $210 million in 2024, driven by increasing research activities in cell apoptosis and related diseases. The market is projected to reach around $350 million by 2034, reflecting a robust growth trajectory fueled by advancements in biotechnology and rising prevalence of cancer and neurodegenerative disorders. AMPK Antibody Market The AMPK antibody market is valued at approximately $1.2 billion, fueled by the growing demand for research products in metabolic diseases and cancer therapy. The market is projected to reach about $2.5 billion by 2034, reflecting accelerating advancements in biotechnology and personalized medicine. Threonine Protein Kinase Chk1 Antibody Insights 2024 The market for Threonine Protein Kinase Chk1 Antibodies is poised for significant growth, with a projected market value of approximately $250 million by 2024. Over the forecast period from 2025 to 2034, the market is expected to expand, reaching an estimated value of $500 million. This growth represents a compound annual growth rate (CAGR) of around 8.5%. TrkC Antibody Market The TrkC antibody market was valued at approximately $1.5 billion in 2024, driven by increasing research funding and rising demand for targeted cancer therapies. This niche market is expected to reach around $3.2 billion by 2034, reflecting a robust growth trajectory. The projected Compound Annual Growth Rate (CAGR) for the period from 2025 to 2034 is estimated at 8.2%. Androgen Antibody Market The androgen antibody market is poised for significant growth, with an estimated market value of approximately $1.2 billion in 2024. Projections indicate that this market could expand to around $2.8 billion by 2034, reflecting increasing demand for advanced diagnostic and therapeutic options in conditions related to androgen imbalance. This growth represents a Compound Annual Growth Rate (CAGR) of about 9.0% during the forecast period from 2025 to 2034. Herpesvirus Entry Mediator HVEM Protein Market The global market for the Herpesvirus Entry Mediator (HVEM) protein is valued at approximately $150 million, primarily driven by its applications in immunotherapy and viral research. The market is poised for significant growth, with a projected value of $300 million by 2034, representing a robust Compound Annual Growth Rate (CAGR) of 7.3% during the forecast period from 2025 to 2034. Histone Deacetylase 1 HDAC1 Antibody Market The market for Histone Deacetylase 1 (HDAC1) antibodies is poised for significant growth, valued at approximately $250 million in 2024. This sector is expected to reach an estimated $750 million by 2034, driven by the rising prevalence of cancer and neurodegenerative diseases, which HDAC1 inhibitors target. The compound annual growth rate (CAGR) is projected at approximately 12% during the forecast period from 2025 to 2034. Prostaglandin-endoperoxide Synthase 2 COX-2 Antibody Market The global market for Prostaglandin-endoperoxide Synthase 2 (COX-2) antibodies is valued at approximately $1.6 billion in 2024, with a projected market value of around $3.2 billion by 2034. This growth corresponds to a robust Compound Annual Growth Rate (CAGR) of about 7.5% during the forecast period from 2025 to 2034. Fecal Incontinence Therapeutics Market The fecal incontinence therapeutics market is poised for significant growth, valued at approximately $1.2 billion in 2024. By 2034, this market is projected to reach around $3 billion, reflecting a robust Compound Annual Growth Rate (CAGR) of 9.2% during the forecast period of 2025–2034. POEMS Syndrome Treatment Market The global market for POEMS Syndrome diagnostic and therapeutic solutions is valued at approximately $700 million. The market is poised for significant growth, with projections estimating a market value of around $1.3 billion by 2034, reflecting a Compound Annual Growth Rate (CAGR) of approximately 6.5% during the forecast period from 2025 to 2034. Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market The Non-Alcoholic Steatohepatitis (NASH) therapeutics and diagnostics market was valued at approximately $4.2 billion in 2024 and is projected to reach $12 billion by 2034. This represents a Compound Annual Growth Rate (CAGR) of around 12% during the forecast period of 2025-2034. mRNA Vaccine and Therapeutics Raw Material Market The global market for mRNA vaccine and therapeutics raw materials is valued at approximately $4.5 billion, driven by the accelerating demand for innovative vaccine solutions and therapeutic modalities. The market is projected to reach around $9.2 billion by 2034, reflecting a robust Compound Annual Growth Rate (CAGR) of approximately 8.2% from 2025 to 2034. Gene Editing Kit Market The gene editing kit market is projected to reach a value of approximately $5.4 billion in 2024, driven by advancements in CRISPR technology and increased applications in synthetic biology and personalized medicine. The market is expected to grow significantly, with a forecasted value of $13.2 billion by 2034, representing a Compound Annual Growth Rate (CAGR) of 9.2% during the forecast period from 2025 to 2034. Nanoparticles Market The global nanoparticles market is projected to reach a value of approximately $60 billion in 2024, driven by advancements in nanotechnology across various sectors, including healthcare, electronics, and energy. The market is expected to grow significantly, achieving a projected value of $120 billion by 2034, reflecting a robust Compound Annual Growth Rate (CAGR) of 7.2% during the forecast period from 2025 to 2034. Bispecific T Cell Engager Therapeutics Future Trends The bispecific T cell engager (BiTE) therapeutics market is valued at approximately $7.5 billion, driven by rising incidences of hematologic malignancies and solid tumors. The market is projected to grow significantly, with an estimated value of around $20 billion by 2034. This represents a compound annual growth rate (CAGR) of about 12.3% over the forecast period from 2025 to 2034. Molecular Cancer Therapeutics Market The global molecular cancer therapeutics market is projected to reach approximately $120 billion in 2024, driven by advancements in personalized medicine and an increasing number of targeted therapies. The market is expected to grow at a robust CAGR of 8.5% from 2025 to 2034, indicating a significant demand for innovative treatments that address specific genetic and molecular profiles of tumors. Single-Cell Dispenser Market The global single-cell dispenser market is valued at approximately $580 million in 2024 and is projected to reach around $1.2 billion by 2034, reflecting a robust Compound Annual Growth Rate (CAGR) of about 7.5% during the forecast period from 2025 to 2034. CONTACT: Irfan Tamboli (Head of Sales) Phone: + 1704 266 3234 Email: sales@ in to access your portfolio
